Tuesday, June 23, 2009

Intraday Trading Calls for 23rd June

Stock Market India may open negative but recovery expected from lower levels and a flat closing expected.

Today's Intraday Stock Tips / Trading Calls (Keep strict Stop Loss for Each Trade):

SCRIP NAME

TRIGGER

PRICE

TARGET 1

TARGET 2

SUZLON

Buy Above

110.10

114.75

120.00

Sell Below

107.25

102.20

96.00

HPCL

Buy Above

307.80

314.75

322.00

Sell Below

302.35

295.45

288.00

SESA GOA

Buy Above

190.20

196.45

202.00

Sell Below

187.10

183.40

178.00

TATA STEEL

Buy Above

405.70

418.40

430.00

Sell Below

398.45

388.20

375.00

ROLTA

Buy Above

130.25

135.45

140.00

Sell Below

128.40

124.15

118.00

IOC

Buy Above

550.15

564.75

580.00

Sell Below

541.35

530.25

515.00

NAGARJUNA CONSTRUCTION

Buy Above

122.70

128.45

135.00

Sell Below

119.20

114.35

108.00

GOOD LUCK

Two Safe Small Cap Pharma Stock

Bal Pharma Ltd.

BSE Code: 524824

NSE Code: BALPHARMA

Last Close: Rs.22.90

Bal Pharma Ltd. (BPL) is a leading Indian pharmaceutical company specialising in prescription drugs, Generics, OTC products, Intravenous Infusion and Bulk Actives with 19 years of experience behind it. Successful operations in the domestic and global markets backed by its strengths in research and its strong infrastructure framework have accelerated BPL's growth from oblivion to US $25 million turnover today. Buoyed by this success, the group has put into motion fast track growth and has set its sight on sales in excess of US $150 million by 2012. The company has four manufacturing units - two in Bangalore, one in Pune and one in Uttarakhand. It has an equity base of Rs.10.45 cr. with huge reserves of around Rs.25 cr. Promoters hold 51.72% stake in the company while the investing public holds only 43.41%. BPL posted a net profit of Rs.3.91 cr. for the first 9 months of FY09 against Rs.2.85 cr. for full FY08. While we expect very good numbers for Q4FY09, the share price fell from Rs.35 to Rs.13 in one year and is currently available at Rs.21 at a P/E ratio of just 8. Buy at every decline with a stop loss of Rs.17. On the upper side, the stock will go up to Rs.27-29 level in the short-term and could go up to Rs.35 level in the medium-term.

Jagsonpal Pharma Ltd.

BSE Code: 507789

NSE Code: JAGSNPHARM

Last Close: Rs.14

Jagsonpal Pharma Ltd. (JPL) is among India's premier pharmaceutical companies. It has substantial R&D, manufacturing, marketing and distribution facilities. Founded in 1964, the company specialises in developing and manufacturing bulk drugs and pharmaceutical formulations. It has an expanding international portfolio of affiliates, joint ventures and representative offices across the globe making it a truly international operation. The firm is represented by 2,500 agents worldwide and has offices in 3 continents. The company's operations span Russia, Brazil, USA, Ukraine, Sri Lanka, Cameroon, Thailand, Argentina, Germany, Switzerland, Korea, Egypt and Vietnam making its reach truly global. Its new plant at Uttarakhand commenced production in April 2008.

The company has an equity of Rs.13.09 cr. with huge reserves of around Rs.60 cr. The promoters hold 65.79% stake while the Indian public holds 26.09% stake. JPL posted a net profit of Rs.5.05 cr. in the first 9 months of FY09 against Rs.3.06 cr. for the whole of FY08. While we expect very good working numbers for the March 2009 quarter, its share price fell from Rs.18 to Rs.6 in just one year and is currently available at Rs.13 at a P/E ratio of just 6. Buy at every decline with a stop loss of Rs.10. On the upper side, the stock will go up to Rs.18-20 level in the short-term and it cold go up to Rs.25 level in the medium-term.

Source: Internet (moneytimes)

Disclaimer

The information in this publication is provided by http://www.moneybazzar.blogspot.com/ is intended for use for Readers & Traders . Every effort is made to provide accurate information, but http://www.moneybazzar.blogspot.com/ cannot guarantee the accuracy of the information or of the market analysis. This is a newsletter and is for informational purposes only. It is not a solicitation or offer to buy or sell futures. There is a high risk of loss in trading futures. You should not trade with money that you cannot afford to lose. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this newsletter. The past performance of any trading system or methodology is not necessarily indicative of future results.



free counter